Lucentis ranibizumab regulatory update

FDA accepted and granted Priority Review to an sBLA from Roche’s Genentech unit for Lucentis ranibizumab to treat myopic choroidal neovascularization. Genentech expects a decision from FDA in 1Q17. Th...